Assessing prescription medications for priority regulatory review.
暂无分享，去创建一个
[1] A. Daemmrich. Pharmacopolitics: Drug Regulation in the United States and Germany , 2004 .
[2] K. Kaitin,et al. Canadian and US Drug Approval Times and Safety Considerations , 2003, The Annals of pharmacotherapy.
[3] N. Rawson. Timeliness of review and approval of new drugs in Canada from 1999 through 2001: is progress being made? , 2003, Clinical therapeutics.
[4] Wayne Kondro,et al. Drug approvals taking too long? , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[5] N. Rawson. Human resources for the approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States. , 2002, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.
[6] C. Milne,et al. Fast Track Product Designation under the Food and Drug Administration Modernization Act: The Industry Experience , 2001 .
[7] N. Rawson. Time required for approval of new drugs in Canada, Australia, Sweden, the United Kingdom and the United States in 1996-1998. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[8] J. R. Landis,et al. The measurement of observer agreement for categorical data. , 1977, Biometrics.